FRITZEMEIER KARL-HEINRICH
No ORCID on file
· 170 papers in corpus
· active 1998-2012
Frequent coauthors
- SCHOELLKOPF KLAUS 153
- STREHLKE PETER 153
- LEHMANN MANFRED 153
- MUHN HANS-PETER 153
- HEINRICH Nikolaus 153
- KRATTENMACHER ROLF 136
- THIEME INA 17
- PRELLE KATJA 17
- PETERS OLAF 17
- BRAEUER NICO 17
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…
2004
This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gesta…